Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)

Home > Drug Product Listings > Mirabegron > Printer-friendly PDF

Mirabegron

Trade Name: Myrbetriq Manufacturer/Distributor: Astellas Pharma Canada Classification: Genitourinary smooth muscle relaxant ATC Class: G04BD - Urinary Status: active Notice of Compliance (yyyy/mm/dd): 2013/03/06 Date Marketed in Canada (yyyy/mm/dd): 2013/03/28 Presentation: (extended release): 25 mg. DIN: 02402874 Tablet (extended release): 50 mg. DIN: 02402882 Comments: Mirabegron is indicated for the treatment of with symptoms of urgency, urgency incontinence and urinary frequency. Keywords: mirabegron bladder diseases Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status: ?

Search Terms:

Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Common Date Marketed in Generic Name Trade Classification Canada Name(s) (yyyy/mm/dd) Doravirine + Delstrigo Antiviral agent 2018/12/15 Lamivudine + Tenofovir Doripenem Doribax Antibacterial agent 2009/09 Silenor Hypnotic 2012/01/08 Dronabinol Marinol Antiemetic 2012/02/24 Dronedarone Multaq Antiarrhythmic agent 2009/08/14 Drospirenone + estetrol Nextstellis Oral contraceptive 2021/06/15 Antithrombotic Drotrecogin alfa Xigris profibrinolytic anti- 2011/10/25 inflammatory enzyme Dulaglutide Trulicity Antihyperglycemic agent 2016/01/08 Skin and mucous Dupilumab Dupixent 2017/11/30 membrane agent Dutasteride + Alpha-1 blocker + 5-Alpha Jalyn 2012/02/03 reductase inhibitor Humanized monoclonal Eculizumab Soliris 2009/06/29 antibody Treatment for amyotrophic Edaravone Radicava 2019/10/29 lateral sclerosis Edoxaban Lixiana Anticoagulant 2017/01 Gonadotropin releasing Elagolix Orilissa hormone receptor 2018/10/31 antagonist Elbasvir + grazoprevir Zepatier Antiviral agent 2016/02/02 Cystic fibrosis Elexacaftor + transmembrane Trikafta 2021/06/22 tezacaftor + ivacaftor conductance regulator correctors Thrombopoietin receptor Eltrombopag Revolade 2011/0404 antagonist Eluxadoline Viberzi Miscellaneous GI drug 2017/05 Eluxadoline Viberzi Miscellaneous GI drugs 2017/04/24 Elvitegravir + cobicistat + Genvoya Antiretroviral agents 2016/02/03 emtricitabine + tenofovir alafenamide Common Date Marketed in Generic Name Trade Classification Canada Name(s) (yyyy/mm/dd) Elvitegravir + Cobicistat + Emtricitabine + Stribild Antiretroviral agent 2012/12/20 Tenofovir disoproxil fumarate Sodium-glucose Empagliflozin Jardiance contransporter 2 (SGLT2) 2015/08/11 inhibitor Empagliflozin + Glyxambi Antidiabetic agent 2016/12/15 linagliptin Empagliflozin + Oral blood glucose Synjardy 2017/09/18 metformin lowering agents Emtricitabine + Descovy Antiretroviral agent 2016/06/03 tenofovir Antineoplastic agent / IDH2 Enasidenib IDHIFA 2019/02/27 Inhibitor Entrectinib Rozlytrek Antineoplastic agent Enzalutamide Xtandi Antineoplastic agent 2013/06/07 Eplerenone Inspra Aldosterone antagonist 2009/02/26 Prevention of migraine; Eptinezumab Vyepti calcitonin gene-related 2021/01/11 peptide binding antibody Erdafitinib Balversa Protein kinase inhibitor 2019/12/09 Anti-calcitonin gene-related Erenumab Aimovig 2018/08/01 peptide receptor Eribulin Halaven Antineoplastic agent 2012/03/10 Sodium-glucose co- Ertugliflozin Steglatro transporter 2 (SGLT2) 2018/05/23 inhibitor Ertugliflozin + Oral blood glucose Segluromet 2018/05/30 metformin lowering agents Ertugliflozin + Oral blood glucose Steglujan 2018/05/22 sitagliptin lowering agents « first? previous 1 2 3 4 5 6 7 8 9 ? next ? last »

© 2017 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions

Source URL (retrieved on 2021-09-24 12:51): http://www.dpic.org/druglisting/mirabegron